Best Life Sciences Companies in Flemish Region, Belgium
The 32 best Life Sciences companies in Flemish Region, Belgium in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Aelin Therapeutics.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Flemish Region
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Aelin Therapeutics Developer of antibiotics based on protein aggregation approach | $32M | 94 mo ago | 35 | Joost Schymkowitz Founder | Series A | 27 patents Small-molecule inhibitors targeting mutant RAS proteins for cancer therapy. | — |
| 2 | AstriVax Developer of prophylactic vaccines for the treatment of infectious diseases | $30M | 34 mo ago | — | Hanne Callewaert Chief Executive Officer | Seed | — | — |
| 3 | reMYND Developer of a drug pipeline programs for neurodegenerative diseases | $29M | 69 mo ago | 46 46 → 28 (-39%) | Joris Winderickx Co-Founder And Sab Member | Series B | 159 patents Small-molecule therapeutics targeting neurodegenerative CNS disorders (aza‑spiroheptanes, triazoles, septin‑6 modulators). | — |
| 4 | TiGenix Allogeneic stem cell-based therapies targeting autoimmune, inflammatory and heart diseases. | $19M | 107 mo ago | 89 | — | Acquired | 81 patents Predictive lymphocyte biomarkers for mesenchymal stromal cell therapy efficacy | — |
| 5 | Rewind Therapeutics Developer of remyelinating therapies for myelin-related diseases | $18M | 45 mo ago | 6 | Anja Harmeier CEO | Series A | 16 patents Novel pyrrolyl‑sulfonamide small molecules targeting GPR17 receptors for neuro‑therapy | — |
| 6 | Cartagenia Software tools to visualize, assess and report clinical genetics data | $9M | 138 mo ago | 158 | — | Acqui-Hired | 10 patents Bioinformatics software for genomic data analysis and cancer copy-number variation detection | — |
| 7 | Pulsify Medical Developer of an ultrasound-based cardiac health monitoring patch | $7M | 66 mo ago | 5 | Lieven Herbots Co-Founder | Series A | 21 patents Medical ultrasound imaging hardware and electronic signal processing systems | — |
| 8 | Trod Medical Developer of RF-based focal ablation devices for tumor | $7M | 156 mo ago | 1 | — | Deadpooled | — | — |
| 9 | ElmediX Developer of the device for treating pancreatic cancer | $5M | 57 mo ago | 12 12 → 17 (+42%) | Johan Van Den Bossche Co-founder and president of the board | Series A | 38 patents Medical thermal therapy and invasive temperature monitoring systems | — |
| 10 | Handl Therapeutics Developer of gene therapy to treat neurodegenerative diseases | $4M | 73 mo ago | 11 | Michael Linden Founder | Acqui-Hired | 2 patents Viral vector gene therapy targeting synucleinopathies (e.g., Parkinson's disease). | — |
| 11 | eSATURNUS Develops imaging technologies and multimedia solutions for operating rooms and hospitals. | $3M | 165 mo ago | — | Thomas Koninckx CEO | Acquired | 18 patents Patents concentrated in electrical & electronics | — |
| 12 | Pepric In vivo imaging using magnetic nanoparticles. | $3M | 142 mo ago | 2 | — | Series A | 21 patents Quantifying magnetic particles via electron paramagnetic resonance analysis | — |
| 13 | Fluidda Provider of functional respiratory imaging and contract research organization services | $3M | 90 mo ago | 12 | — | Late Stage | 13 patents Pulmonary hyperinflation treatment devices and patient-specific airflow modeling for lung therapy | — |
| 14 | Formac Pharma Drug delivery solutions for poorly soluble APIs | $2M | 131 mo ago | 3 | Laurens Theunis Co-Founder | Seed | — | — |
| 15 | Ectosense Provider of connected solutions for monitoring sleep disorders | $2M | 103 mo ago | 9 | Frederik Massie Co-Founder & CTO | Acquired | 55 patents Sleep monitoring and peripheral arterial tone diagnostic medical devices | — |
| 16 | Flamingo Developer of RNA-based therapeutics for oncology | $2M | 40 mo ago | 15 | Floor Stam Co-Founder & COO | Funding Raised | 4 patents Retractable dog leash mechanisms and accessories for pet control | — |
| 17 | DName-iT Provider of a sequence-based genetic testing platform | $631K | 40 mo ago | 1 | Harry Cuppens Founder & CSO | Seed | 16 patents Nucleic acid‑based sample identification and profiling technologies | — |
| 18 | ATLAS Neuroengineering Silicon based probes | $615K | 44 mo ago | — | Arno Aarts Co-Founder & CEO | Public | 6 patents Neural interface probes and hyperdrive stimulation devices for precise neuron recording and stimulation | — |
Top 12 Life Sciences companies in Flemish Region
#1
Seed · Leuven, Flemish Region · founded 2022$29.9Mraised▾
Developer of prophylactic vaccines for the treatment of infectious diseases. The company uses DNA-based technology to develop the plasmid-launched live attenuated virus platform for targeted delivery and immune response. The company has developed a product pipeline for Yellow Fever, Rabies, and Chronic Hepatitis B.
- Dec 2023Grant (prize money)$3.2M
- May 2023Grant (prize money)$2.7M
- Aug 2022Seed$29.9M
#2
Series A · Leuven, Flemish Region · founded 2017 · 6 employees$18.2Mraised▾
Developer of remyelinating therapies for myelin-related diseases. The company's approach is based on ensuring the proper functioning of myelinating oligodendrocytes and oligodendrocyte precursor cells (OPCs )to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis or nerve injuries.
- Jan 2023Series A—
- Aug 2019Grant (prize money)$3.2M
- Jan 2018Series A$18.2M
#3
Funding Raised · Leuven, Flemish Region · founded 2019 · 15 employees$1.8Mraised▾
Developer of RNA-based therapeutics for oncology. The company's products include Danvatirsen for neck and head squamous cell carcinoma, AR for prostate cancer, IRF4 for multiple myeloma, MALATI for breast cancer, and others. The platform FLAME exploits lncRNA biology and identifies targets that are exquisitely sensitive to antisense modulation.
- Jun 2023Grant (prize money)$1.8M
#4
Series B · Leuven, Flemish Region · founded 2002 · 46 employees$29.1Mraised▾
reMYND is a CRO that is also developing a drug pipeline for neurodegenerative diseases. The company provides in vivo contract research services based on its proprietary mouse models: progressive amyloid-o-pathy (APP), progressive tau-o-pathy (TAU) and an APP + TAU model. Its drug discovery program is focused on small molecule therapeutics for neurodegenerative diseases, specifically those caused by protein-misfolding. Its lead candidate is completing IND-enabling studies for Alzheimer's disease. In company has three other candidates for Alzheimer's disease, two for diabetes, two for Parkinson's disease, and one candidate each for Huntington's disease and amyloid lateral sclerosis.
- Jan 2021Series B$14.6M
- Dec 2018Series B$13.6M
- Mar 2016Grant (prize money)$524.8K
- Jun 2011Grant (prize money)$2.1M
#5
Seed · Leuven, Flemish Region · founded 2014 · 1 employees$631.3Kraised▾
DName-iT has developed a platform for genetic diagnosis using NGS. The company's proprietary technology includes DName that is able to analyse unique DNA barcodes for the detection of disease. The company uses DName technology to overcome the problems that occurred in NGS technology.
- Jun 2023Seed$631.3K
#6
Public · Leuven, Flemish Region · founded 2012$614.5Kraised▾
ATLAS Neuroengineering is a spin-off company of imec, Leuven and IMTEK, University of Freiburg, established with the technology developed under European FP6 program “NeuroProbes”. The product portfolio includes a wide range of silicon-based probes comprising typically 8 to 64 electrodes per probe and electronic depth control (EDC) probes. The company is specialized in silicon microfabrication, system integration, biocompatibility, and histology. It offers tools and solutions for the experimental neuroscience to record and stimulate neuronal activity. In addition, it offers high-density, silicon-based neural probes for application in cortical and thalamic brain applications as well as for intraspinal microstimulation (ISMS).
- Mar 2023Grant (prize money)$192K
- Mar 2021Grant (prize money)$308.7K
- Jan 2021Grant (prize money)$113.9K
#7
Series A · Leuven, Flemish Region · founded 2019 · 5 employees$7.4Mraised▾
Developer of an ultrasound-based cardiac health monitoring patch. It tracks cardiac output, stroke volume, and the left ventricle’s ejection to detect insufficient cardiac performance and reduce risks. It continuously measures and monitors cardiac performance. It also has features for data collection, capture, and analysis.
- May 2021Grant (prize money)$2M
- May 2021Series A$4.5M
- Oct 2019Seed$2.9M
#8
Series A · Leuven, Flemish Region · founded 2015 · 12 employees$4.5Mraised▾
Developer of the device for treating pancreatic cancer. The device provides heat that increases tumor sensitivity to chemo- or radiotherapy through a combination of physiological mechanisms.
- Jan 2022Series A$4.5M
#9
Acquired · Leuven, Flemish Region · founded 2000 · 89 employees$19Mraised▾
TiGenix focused on developing and commercialising novel therapeutics from its validated, proprietary platform of donor-derived (allogeneic) expanded adipose-derived stem cells (eASCs). Its lead eASCs programmes include Cx601, a suspension of allogeneic eASCs which is being developed for the treatment of perianal fistulas in Crohn’s disease patients; Cx611, an allogeneic eASCs which is being developed to treat rheumatoid arthritis, sepsis. Its AlloCSC-01 pipeline includes allogeneic cardiac stem cells for the treatment of acute ischaemic heart disease. Its commercialised product, ChondroCelect is for cartilage repair in the knee and was the first cell-based product approved in Europe.
- Nov 2017Post IPO$25.9K
- Mar 2016Post IPO$26.1M
- Nov 2015Post IPO$9.2M
- Nov 2015Grant (prize money)$320.5K
#10
Series A · Leuven, Flemish Region · founded 2017 · 35 employees$31.8Mraised▾
Aelin Therapeutics is developing antibiotics based on the protein aggregation approach. The company is developing antibiotics that penetrate bacterial cells and induce protein aggregation, which leads to the death of bacteria. The molecules showed strong antibacterial (bactericidal) activity against gram-negative bacteria. The company claims that their molecules will be useful to treat a wide array of infections including drug resistance species. It's flagship product Pept-ins which can kill the gram-negative bacteria.
- Dec 2018Grant (prize money)$1.1M
- Dec 2017Series A$31.8M
#11
Acqui-Hired · Leuven, Flemish Region · founded 2008 · 158 employees$8.8Mraised▾
Cartagenia supplies variant assessment support and lab report automation software, database systems, and related services to genetic labs, pathology labs and clinicians, enabling them to perform clinically relevant genetic analyses and offer patients genetic interpretation and counseling. Cartagenia Bench Lab allows automation of variant assessment protocols and lab report generation for structural and molecular variant assays such as Arrays, Sanger and Next Generation Sequencing. It supports communication with referring physicians, allows labs and clinicians to put variants in their clinical context, and supports confident data sharing.
- May 2015Grant (prize money)$211.1K
- Jan 2015Grant (prize money)$78.6K
- May 2014Series B$5.9M
- Oct 2011Series A$2.9M
#12
Acqui-Hired · Leuven, Flemish Region · founded 2019 · 11 employees$3.6Mraised▾
Developer of gene therapy to treat neurodegenerative diseases. The company is developing in vivo gene therapy using its proprietary adeno-associated virus (AAV) capsid technology to treat central nervous system (CNS) diseases.
- Sep 2020Grant (prize money)$3.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Belgium
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 357 Belgium-affiliated papers.
- KU Leuven58
- Ghent University57
- Triphase36
- Flanders Marine Institute23
- University of Liège22
- Bioprocess3
- Cell biology3
- Mutant3
- Molecular biology3
- Immune system3
- Population1→5
- Antibiotics1→4
- Gene2→4
- Probiotic5
- Food science5
- Population5
- Agriculture5
- Antimicrobial4
Where biotechnology is researched across Belgium
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.